1084 related articles for article (PubMed ID: 25434822)
1. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9.
Li HL; Fujimoto N; Sasakawa N; Shirai S; Ohkame T; Sakuma T; Tanaka M; Amano N; Watanabe A; Sakurai H; Yamamoto T; Yamanaka S; Hotta A
Stem Cell Reports; 2015 Jan; 4(1):143-154. PubMed ID: 25434822
[TBL] [Abstract][Full Text] [Related]
2. Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells.
Ifuku M; Iwabuchi KA; Tanaka M; Lung MSY; Hotta A
Methods Mol Biol; 2018; 1828():191-217. PubMed ID: 30171543
[TBL] [Abstract][Full Text] [Related]
3. Targeted addition of mini-dystrophin into rDNA locus of Duchenne muscular dystrophy patient-derived iPSCs.
Zeng B; Zhou M; Liu B; Shen F; Xiao R; Su J; Hu Z; Zhang Y; Gu A; Wu L; Liu X; Liang D
Biochem Biophys Res Commun; 2021 Mar; 545():40-45. PubMed ID: 33540285
[TBL] [Abstract][Full Text] [Related]
4. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing.
Chemello F; Chai AC; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Atmanli A; Mireault AA; Liu N; Bassel-Duby R; Olson EN
Sci Adv; 2021 Apr; 7(18):. PubMed ID: 33931459
[TBL] [Abstract][Full Text] [Related]
5. A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.
Young CS; Hicks MR; Ermolova NV; Nakano H; Jan M; Younesi S; Karumbayaram S; Kumagai-Cresse C; Wang D; Zack JA; Kohn DB; Nakano A; Nelson SF; Miceli MC; Spencer MJ; Pyle AD
Cell Stem Cell; 2016 Apr; 18(4):533-40. PubMed ID: 26877224
[TBL] [Abstract][Full Text] [Related]
6. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.
Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ
J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells.
Min YL; Li H; Rodriguez-Caycedo C; Mireault AA; Huang J; Shelton JM; McAnally JR; Amoasii L; Mammen PPA; Bassel-Duby R; Olson EN
Sci Adv; 2019 Mar; 5(3):eaav4324. PubMed ID: 30854433
[TBL] [Abstract][Full Text] [Related]
8. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy.
Pickar-Oliver A; Gough V; Bohning JD; Liu S; Robinson-Hamm JN; Daniels H; Majoros WH; Devlin G; Asokan A; Gersbach CA
Mol Ther; 2021 Nov; 29(11):3243-3257. PubMed ID: 34509668
[TBL] [Abstract][Full Text] [Related]
9. Functional correction of dystrophin actin binding domain mutations by genome editing.
Kyrychenko V; Kyrychenko S; Tiburcy M; Shelton JM; Long C; Schneider JW; Zimmermann WH; Bassel-Duby R; Olson EN
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931764
[TBL] [Abstract][Full Text] [Related]
10. From gRNA Identification to the Restoration of Dystrophin Expression: A Dystrophin Gene Correction Strategy for Duchenne Muscular Dystrophy Mutations Using the CRISPR-Induced Deletion Method.
Duchêne B; Iyombe-Engembe JP; Rousseau J; Tremblay JP; Ouellet DL
Methods Mol Biol; 2018; 1687():267-283. PubMed ID: 29067670
[TBL] [Abstract][Full Text] [Related]
11. Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing.
Min YL; Chemello F; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Mireault AA; McAnally JR; Shelton JM; Zhang Y; Bassel-Duby R; Olson EN
Mol Ther; 2020 Sep; 28(9):2044-2055. PubMed ID: 32892813
[TBL] [Abstract][Full Text] [Related]
12. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy.
Moretti A; Fonteyne L; Giesert F; Hoppmann P; Meier AB; Bozoglu T; Baehr A; Schneider CM; Sinnecker D; Klett K; Fröhlich T; Rahman FA; Haufe T; Sun S; Jurisch V; Kessler B; Hinkel R; Dirschinger R; Martens E; Jilek C; Graf A; Krebs S; Santamaria G; Kurome M; Zakhartchenko V; Campbell B; Voelse K; Wolf A; Ziegler T; Reichert S; Lee S; Flenkenthaler F; Dorn T; Jeremias I; Blum H; Dendorfer A; Schnieke A; Krause S; Walter MC; Klymiuk N; Laugwitz KL; Wolf E; Wurst W; Kupatt C
Nat Med; 2020 Feb; 26(2):207-214. PubMed ID: 31988462
[TBL] [Abstract][Full Text] [Related]
13. Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases.
Ousterout DG; Kabadi AM; Thakore PI; Perez-Pinera P; Brown MT; Majoros WH; Reddy TE; Gersbach CA
Mol Ther; 2015 Mar; 23(3):523-32. PubMed ID: 25492562
[TBL] [Abstract][Full Text] [Related]
14. Full-Length Dystrophin Restoration via Targeted Exon Addition in DMD-Patient Specific iPSCs and Cardiomyocytes.
Xiao R; Zhou M; Wang P; Zeng B; Wu L; Hu Z; Liang D
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012442
[TBL] [Abstract][Full Text] [Related]
15. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human
Egorova TV; Zotova ED; Reshetov DA; Polikarpova AV; Vassilieva SG; Vlodavets DV; Gavrilov AA; Ulianov SV; Buchman VL; Deykin AV
Dis Model Mech; 2019 Apr; 12(4):. PubMed ID: 31028078
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
18. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S
J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
[TBL] [Abstract][Full Text] [Related]
19. Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations.
Maggio I; Stefanucci L; Janssen JM; Liu J; Chen X; Mouly V; Gonçalves MA
Nucleic Acids Res; 2016 Feb; 44(3):1449-70. PubMed ID: 26762977
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a Duchenne muscular dystrophy patient-derived induced pluripotent stem cell line carrying a deletion of exons 51-53 of the dystrophin gene (CCMi003-A).
Rovina D; Castiglioni E; Farini A; Bellichi M; Gervasini C; Paganini S; Di Segni M; Santoro R; Torrente Y; Pompilio G; Gowran A
Stem Cell Res; 2019 Oct; 40():101544. PubMed ID: 31465894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
